What is the recommended capillary blood glucose monitoring schedule and targets for a patient on a subcutaneous insulin sliding‑scale regimen?

Capillary Blood Glucose Monitoring for Subcutaneous Insulin Sliding Scale

For hospitalized patients on subcutaneous insulin sliding scale, capillary blood glucose (CBG) should be monitored before meals (3 times daily) in patients who are eating, or every 4-6 hours in patients who are NPO (nil per os), with glycemic targets of 140-180 mg/dL for most non-critically ill patients. 1, 2, 3

Monitoring Schedule

For Patients Who Are Eating

• Check CBG before each meal (typically 3 times daily: breakfast, lunch, dinner)
• Additional bedside checks may be needed if hypoglycemia is suspected
• More frequent monitoring (every 1-2 hours initially, then every 4 hours) is required if on IV insulin infusion 4

For NPO Patients

• Check CBG every 4-6 hours around the clock
• This maintains surveillance for both hyperglycemia and hypoglycemia 1, 2, 3

Glycemic Targets

Target Range: 140-180 mg/dL (7.8-10.0 mmol/L) for most hospitalized non-critically ill patients 1, 2, 3

• Initiate insulin therapy when blood glucose persistently exceeds 180 mg/dL (10.0 mmol/L) 2, 3
• More stringent targets of 110-140 mg/dL may be considered for select patients (e.g., post-cardiac surgery) if achievable without significant hypoglycemia 2
• Avoid targeting euglycemia (80-110 mg/dL) as this significantly increases hypoglycemia risk and mortality 4, 2

Critical Caveat: Sliding Scale Insulin Alone is Inadequate

Sliding scale insulin (SSI) as monotherapy is strongly discouraged and should be avoided in most hospitalized patients with diabetes. 1, 5, 6, 7, 8 Here's why:

Evidence Against SSI Monotherapy

• SSI achieves target glycemic control in only 6-12% of patients over 5 days 6
• 84% of SSI injections result in subtherapeutic effects with persistently elevated glucose 6
• SSI is reactive rather than proactive, treating hyperglycemia after it occurs rather than preventing it 5, 9
• Guidelines have advised against SSI monotherapy for nearly 20 years 8

When SSI Alone May Be Acceptable

The only appropriate use of SSI monotherapy is in highly selected patients 1, 7:

• Admission glucose <180 mg/dL (ideally <140 mg/dL)
• No prior insulin use or very low home insulin doses
• Mild stress hyperglycemia in patients without established diabetes
• In these limited cases, 83-86% achieve target control 7

Preferred Approach: Scheduled Insulin Regimens

For patients requiring insulin, use scheduled basal-bolus or basal-plus regimens rather than SSI alone 1, 5, 9:

Basal-Bolus Regimen (for moderate-severe hyperglycemia)

• Basal insulin (long-acting): 50% of total daily dose, given once or twice daily
• Prandial insulin (rapid-acting): 50% of total daily dose, divided before meals
• Plus correction insulin for elevated pre-meal readings
• Starting dose: 0.3-0.5 units/kg/day for insulin-naive patients 5

Basal-Plus Regimen (for mild hyperglycemia)

• Basal insulin: 0.1-0.25 units/kg/day
• Plus correction doses of rapid-acting insulin before meals or every 6 hours if NPO 5
• Appropriate for patients with admission glucose 140-200 mg/dL 5

Monitoring Technique Requirements

• Use FDA-approved point-of-care hospital-calibrated glucose meters 2, 3
• Use the same glucose meter and same batch of test strips throughout hospitalization 10
• Obtain measurements when blood glucose is relatively stable (before meals, before bedtime) 10
• Capillary blood glucose may be inaccurate in patients with poor perfusion, edema, anemia, or on certain medications 4, 2
• Consider arterial blood glucose if arterial line is present, as it's more accurate than capillary 4

Emerging Technology: Continuous Glucose Monitoring

Personal CGM devices may be continued during hospitalization if the patient is already using one, with confirmatory POC glucose checks for insulin dosing decisions 1, 2, 3. CGM provides advantages in:

• Detecting nocturnal and asymptomatic hypoglycemia 2, 3, 11
• Increasing time-in-range (53.5% vs 35% with standard monitoring) 11
• Reducing hyperglycemic episodes 11

However, CGM requires confirmatory POC capillary glucose for all insulin dosing decisions and hypoglycemia treatment 1, 2.

Common Pitfalls to Avoid

1. Don't use SSI monotherapy in patients with established diabetes on home insulin—this leads to poor control 6, 8
2. Don't target tight control (<110 mg/dL)—this increases hypoglycemia and mortality 4, 2
3. Don't rely solely on CGM for insulin dosing without POC confirmation 1, 2
4. Don't forget to adjust regimens—81% of patients on SSI never have their regimen adjusted despite persistent hyperglycemia 6
5. Don't use premixed insulin in the hospital—unacceptably high hypoglycemia rates 5